Latest From AliveCor Inc.
The latest Apple Watch includes an electrocardiogram that has received de novo clearance from US FDA to detect irregular heart rhythms. The approval, say two top US FDA regulators, is a signal to the digital health industry that the agency is trying to help them innovate.
Atrial fibrillation is always a hot topic at cardiology conferences and this year's European Society of Cardiology Congress in Barcelona was no exception. The meeting highlighted data from a spate of key clinical studies providing more insight into this heart condition, including the CASTLE-AF and CAPTAF studies, which further affirmed the benefits of catheter ablation. Outcomes were also reported from REHEARSE-AF and AFFIRM.
Pharma does not need to make wearables. Instead, it needs to figure out how best to use the data that these technologies can provide, how to integrate wearables into product offerings and how to persuade payers to foot the bill. Investment in this field is increasing as the potential of mobile and wearable technologies to transform therapeutic development and healthcare delivery becomes clear.
Patient-centric R&D is imperative for pharma in delivering effective medicines and better outcomes. The push to implement it is challenging long-held biopharma business practices, including how clinical trials are designed, recruited and run – and what they measure.
- Monitoring Equipment & Devices
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- AliveCor Inc.
- Senior Management
Priya Abani, CEO
Jacqueline Shreibati, MD, CMO
- Contact Info
Phone: (855) 338-8800
140 Geary St.
San Francisco, CA 94108
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.